Australia’s CSL to invest up to $505 mln in Dutch biotech VarmX
PositiveFinancial Markets

Australia's CSL is set to invest up to $505 million in Dutch biotech company VarmX, marking a significant commitment to advancing innovative therapies.
Editor’s Note: This investment highlights CSL's dedication to expanding its portfolio in the biotech sector, which could lead to groundbreaking treatments and strengthen its position in the global market.
— Curated by the World Pulse Now AI Editorial System